Comparative manufacture and cell-based delivery of antiretroviral nanoformulations

Shantanu Balkundi1, Ari S Nowacek1, Ram S Veerubhotla1, Han Chen2, Andrea Martinez-Skinner1, Upal Roy1, R Lee Mosley1,3, Georgette Kanmogne1, Xinming Liu1,3,4, Alexander V Kabanov3,4, Tatiana Bronich3,4, JoEllyn McMillan1, Howard E Gendelman1,31Department of Pharmacology and Experimental Neuroscienc...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Balkundi S, Nowacek AS, Veerubhotla RS, Chen H, Martinez-Skinner A, Roy U, Mosley RL, Kanmogne G, Liu X, Kabanov AV, Bronich T, McMillan J, Gendelman HE
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/3116847039a74ce9ab92631e7e4f7562
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3116847039a74ce9ab92631e7e4f7562
record_format	dspace
spelling	oai:doaj.org-article:3116847039a74ce9ab92631e7e4f75622021-12-02T00:40:15ZComparative manufacture and cell-based delivery of antiretroviral nanoformulations1176-91141178-2013https://doaj.org/article/3116847039a74ce9ab92631e7e4f75622011-12-01T00:00:00Zhttp://www.dovepress.com/comparative-manufacture-and-cell-based-delivery-of-antiretroviral-nano-a8925https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Shantanu Balkundi1, Ari S Nowacek1, Ram S Veerubhotla1, Han Chen2, Andrea Martinez-Skinner1, Upal Roy1, R Lee Mosley1,3, Georgette Kanmogne1, Xinming Liu1,3,4, Alexander V Kabanov3,4, Tatiana Bronich3,4, JoEllyn McMillan1, Howard E Gendelman1,31Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA; 2Center for Biotechnology, University of Nebraska-Lincoln, Lincoln, NE, USA; 3Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE, USA; 4Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USAAbstract: Nanoformulations of crystalline indinavir, ritonavir, atazanavir, and efavirenz were manufactured by wet milling, homogenization or sonication with a variety of excipients. The chemical, biological, immune, virological, and toxicological properties of these formulations were compared using an established monocyte-derived macrophage scoring indicator system. Measurements of drug uptake, retention, release, and antiretroviral activity demonstrated differences amongst preparation methods. Interestingly, for drug cell targeting and antiretroviral responses the most significant difference among the particles was the drug itself. We posit that the choice of drug and formulation composition may ultimately affect clinical utility.Keywords: human immunodeficiency virus type one, nanotoxicology, monocyte-derived macrophage, nanoformulated antiretroviral therapy, manufacturing techniquesBalkundi SNowacek ASVeerubhotla RSChen HMartinez-Skinner ARoy UMosley RLKanmogne GLiu XKabanov AVBronich TMcMillan JGendelman HEDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2011, Iss default, Pp 3393-3404 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Balkundi S Nowacek AS Veerubhotla RS Chen H Martinez-Skinner A Roy U Mosley RL Kanmogne G Liu X Kabanov AV Bronich T McMillan J Gendelman HE Comparative manufacture and cell-based delivery of antiretroviral nanoformulations
description	Shantanu Balkundi1, Ari S Nowacek1, Ram S Veerubhotla1, Han Chen2, Andrea Martinez-Skinner1, Upal Roy1, R Lee Mosley1,3, Georgette Kanmogne1, Xinming Liu1,3,4, Alexander V Kabanov3,4, Tatiana Bronich3,4, JoEllyn McMillan1, Howard E Gendelman1,31Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA; 2Center for Biotechnology, University of Nebraska-Lincoln, Lincoln, NE, USA; 3Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, Omaha, NE, USA; 4Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USAAbstract: Nanoformulations of crystalline indinavir, ritonavir, atazanavir, and efavirenz were manufactured by wet milling, homogenization or sonication with a variety of excipients. The chemical, biological, immune, virological, and toxicological properties of these formulations were compared using an established monocyte-derived macrophage scoring indicator system. Measurements of drug uptake, retention, release, and antiretroviral activity demonstrated differences amongst preparation methods. Interestingly, for drug cell targeting and antiretroviral responses the most significant difference among the particles was the drug itself. We posit that the choice of drug and formulation composition may ultimately affect clinical utility.Keywords: human immunodeficiency virus type one, nanotoxicology, monocyte-derived macrophage, nanoformulated antiretroviral therapy, manufacturing techniques
format	article
author	Balkundi S Nowacek AS Veerubhotla RS Chen H Martinez-Skinner A Roy U Mosley RL Kanmogne G Liu X Kabanov AV Bronich T McMillan J Gendelman HE
author_facet	Balkundi S Nowacek AS Veerubhotla RS Chen H Martinez-Skinner A Roy U Mosley RL Kanmogne G Liu X Kabanov AV Bronich T McMillan J Gendelman HE
author_sort	Balkundi S
title	Comparative manufacture and cell-based delivery of antiretroviral nanoformulations
title_short	Comparative manufacture and cell-based delivery of antiretroviral nanoformulations
title_full	Comparative manufacture and cell-based delivery of antiretroviral nanoformulations
title_fullStr	Comparative manufacture and cell-based delivery of antiretroviral nanoformulations
title_full_unstemmed	Comparative manufacture and cell-based delivery of antiretroviral nanoformulations
title_sort	comparative manufacture and cell-based delivery of antiretroviral nanoformulations
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/3116847039a74ce9ab92631e7e4f7562
work_keys_str_mv	AT balkundis comparativemanufactureandcellbaseddeliveryofantiretroviralnanoformulations AT nowacekas comparativemanufactureandcellbaseddeliveryofantiretroviralnanoformulations AT veerubhotlars comparativemanufactureandcellbaseddeliveryofantiretroviralnanoformulations AT chenh comparativemanufactureandcellbaseddeliveryofantiretroviralnanoformulations AT martinezskinnera comparativemanufactureandcellbaseddeliveryofantiretroviralnanoformulations AT royu comparativemanufactureandcellbaseddeliveryofantiretroviralnanoformulations AT mosleyrl comparativemanufactureandcellbaseddeliveryofantiretroviralnanoformulations AT kanmogneg comparativemanufactureandcellbaseddeliveryofantiretroviralnanoformulations AT liux comparativemanufactureandcellbaseddeliveryofantiretroviralnanoformulations AT kabanovav comparativemanufactureandcellbaseddeliveryofantiretroviralnanoformulations AT bronicht comparativemanufactureandcellbaseddeliveryofantiretroviralnanoformulations AT mcmillanj comparativemanufactureandcellbaseddeliveryofantiretroviralnanoformulations AT gendelmanhe comparativemanufactureandcellbaseddeliveryofantiretroviralnanoformulations
_version_	1718403545752928256

Comparative manufacture and cell-based delivery of antiretroviral nanoformulations

Ejemplares similares